Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:2152 |
Name | ovary epithelial cancer |
Definition | An ovarian cancer that is derives_from ovarian surface epithelium. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer ovarian cancer ovary epithelial cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
MSH6 negative | Pembrolizumab | ovary epithelial cancer | sensitive | detail... |
MLH1 negative | Pembrolizumab | ovary epithelial cancer | sensitive | detail... |
MSH6 negative | Dostarlimab-gxly | ovary epithelial cancer | sensitive | detail... |
MLH1 negative | Dostarlimab-gxly | ovary epithelial cancer | sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | ovary epithelial cancer | sensitive | detail... |
RET fusion | Selpercatinib | ovary epithelial cancer | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00703105 | Phase II | Denileukin diftitox | Ovarian Dendritic Cell Vaccine Trial | Unknown status | USA | 0 |
NCT01012817 | Phase Ib/II | Topotecan + Veliparib | Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer | Active, not recruiting | USA | 0 |
NCT01116648 | Phase Ib/II | Olaparib Cediranib + Olaparib | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT01145430 | Phase I | Pegylated liposomal doxorubicin + Veliparib | Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer | Completed | USA | 0 |
NCT01146795 | Phase II | Bevacizumab + Carboplatin + Paclitaxel | Neoadjuvant Therapy for Ovarian Cancer | Completed | USA | 0 |
NCT01239732 | Phase III | Bevacizumab + Carboplatin + Paclitaxel | A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer | Completed | TUR | SWE | SVN | SVK | ROU | POL | NLD | LVA | LTU | ITA | ISR | IRL | HUN | GRC | FRA | EST | ESP | DNK | CHE | CAN | BRA | BGR | AUT | ARG | 13 |
NCT01482715 | Phase Ib/II | Rucaparib | A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) | Completed | USA | ISR | GBR | ESP | CAN | 0 |
NCT01519869 | Phase I | Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma | Completed | USA | 0 | |
NCT01535157 | Phase Ib/II | Ketoconazole Fenretinide | Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer | Terminated | USA | 0 |
NCT01536743 | Phase II | Palbociclib | A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression | Completed | USA | 0 |
NCT01649336 | Phase I | Binimetinib + Paclitaxel | A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | Completed | USA | 0 |
NCT01690468 | Phase Ib/II | Carboplatin + Triciribine | PTX-200 and Carboplatin in Ovarian Cancer | Terminated | USA | 0 |
NCT01749397 | Phase I | Floxuridine + Veliparib | Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer | Completed | USA | 0 |
NCT01846611 | Phase III | Pegylated liposomal doxorubicin Dexamethasone | A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Completed | USA | POL | NZL | ISR | GBR | CHE | AUS | 3 |
NCT01853644 | Phase II | Tivozanib | Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Completed | USA | 0 |
NCT01891344 | Phase II | Rucaparib | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | Completed | USA | GBR | FRA | ESP | CAN | AUS | 0 |
NCT01968213 | Phase III | Rucaparib | A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer | Completed | USA | NZL | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 0 |
NCT01991210 | Phase II | DNIB0600A Pegylated liposomal doxorubicin | A Randomized Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer | Terminated | USA | POL | GBR | FRA | ESP | CAN | BEL | 0 |
NCT02033616 | Phase II | Ovapuldencel-T | Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas | Unknown status | USA | 0 |
NCT02091999 | Phase I | Enfortumab vedotin-ejfv | A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 | Completed | USA | CAN | 0 |
NCT02178722 | Phase Ib/II | Epacadostat + Pembrolizumab | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | Completed | USA | 0 |
NCT02187848 | Phase Ib/II | SAR408701 | Evaluation of SAR408701 in Patients With Advanced Solid Tumors | Terminated | USA | FRA | ESP | CAN | 1 |
NCT02188550 | Phase II | Everolimus + Letrozole | Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer | Unknown status | USA | 0 |
NCT02195973 | Phase Ib/II | Paclitaxel + Sonidegib | Phase IB/II Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer | Completed | USA | 0 |
NCT02264678 | Phase Ib/II | Ceralasertib Carboplatin + Ceralasertib Ceralasertib + Durvalumab Ceralasertib + Olaparib | Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents | Recruiting | USA | HUN | GBR | FRA | ESP | CAN | BEL | AUS | 1 |
NCT02272790 | Phase II | Adavosertib + Pegylated liposomal doxorubicin Adavosertib + Carboplatin Adavosertib + Gemcitabine Adavosertib + Paclitaxel | Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Completed | USA | NLD | CAN | 0 |
NCT02275039 | Phase I | MVAp53 Gemcitabine | p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer | Completed | USA | 0 |
NCT02278783 | Phase II | Regorafenib | Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer | Terminated | USA | 0 |
NCT02289950 | Phase II | Farletuzumab | A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer | Completed | USA | ITA | GBR | ESP | DEU | BEL | 1 |
NCT02354131 | Phase Ib/II | Niraparib Bevacizumab + Niraparib | Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer (AVANOVA) | Completed | USA | DNK | 0 |
NCT02364713 | Phase II | Pegylated liposomal doxorubicin Bevacizumab + Topotecan Topotecan Paclitaxel MV-NIS Bevacizumab + Paclitaxel Bevacizumab + Pegylated liposomal doxorubicin Gemcitabine | MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer | Active, not recruiting | USA | 0 |
NCT02392676 | Phase III | Olaparib | Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations | Withdrawn | USA | GBR | 3 |
NCT02534922 | Phase I | Prolanta | Study of Prolanta in Recurrent or Persistent Epithelial Ovarian Cancer (ProlantaOC) | Unknown status | USA | 0 |
NCT02537444 | Phase II | Acalabrutinib Pembrolizumab | ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer (KEYNOTE191) | Completed | USA | 0 |
NCT02539719 | Phase I | Budigalimab + SC-003 SC-003 | Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer | Terminated | USA | 0 |
NCT02540356 | Phase Ib/II | Imalumab | Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer | Terminated | USA | 0 |
NCT02611024 | Phase Ib/II | Irinotecan + Lurbinectedin | Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors | Recruiting | USA | ITA | FRA | ESP | DEU | CHE | 0 |
NCT02644369 | Phase II | Pembrolizumab | Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors (INSPIRE) | Active, not recruiting | CAN | 0 |
NCT02657889 | Phase Ib/II | Niraparib + Pembrolizumab | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (TOPACIO) | Completed | USA | 0 |
NCT02660034 | Phase I | Pamiparib + Tislelizumab | The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors | Completed | USA | NZL | GBR | FRA | ESP | AUS | 0 |
NCT02674061 | Phase II | Pembrolizumab | Efficacy and Safety Study of Pembrolizumab (MK-3475) in Women With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100) | Completed | 0 | |
NCT02713386 | Phase Ib/II | Ruxolitinib Carboplatin + Paclitaxel | Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | USA | 0 |
NCT02718417 | Phase III | Avelumab Carboplatin + Paclitaxel | Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) | Terminated | USA | TUR | SVK | ROU | POL | NLD | LVA | ITA | IRL | HUN | HRV | GBR | EST | DEU | CHE | CAN | BGR | 8 |
NCT02726997 | Phase Ib/II | Carboplatin + Durvalumab + Paclitaxel | Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer | Active, not recruiting | USA | 0 |
NCT02728830 | Phase I | Pembrolizumab | A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers | Completed | USA | 0 |
NCT02766582 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab | Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer | Completed | USA | 0 |
NCT02785250 | Phase I | Cyclophosphamide + Epacadostat + Maveropepimut-S | Study of DPX-Survivac Vaccine Therapy and Epacadostat in Patients With Recurrent Ovarian Cancer | Active, not recruiting | USA | CAN | 0 |
NCT02788708 | Phase I | Lenvatinib + Paclitaxel | Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer | Completed | USA | 0 |
NCT02811497 | Phase II | Azacitidine + Durvalumab | Study of Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR) | Completed | CAN | 0 |
NCT02824042 | Phase I | Anetumab ravtansine + Itraconazole Anetumab ravtansine | Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole | Completed | USA | NLD | FRA | ESP | BEL | AUS | 0 |
NCT02833506 | Phase I | NY-ESO-1 peptide vaccine + Sirolimus NY-ESO-1 peptide vaccine | Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Withdrawn | USA | 0 |
NCT02834975 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab | Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC). | Terminated | USA | 0 |
NCT02853318 | Phase II | Bevacizumab + Cyclophosphamide + Pembrolizumab | Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Completed | USA | 0 |
NCT02855944 | Phase III | Cisplatin Rucaparib Carboplatin Gemcitabine Paclitaxel | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Completed | USA | POL | ITA | ISR | HUN | GBR | ESP | CZE | CAN | BRA | 2 |
NCT02865811 | Phase II | Pegylated liposomal doxorubicin + Pembrolizumab | Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer | Completed | USA | 0 |
NCT02873962 | Phase II | Bevacizumab + Nivolumab | A Phase II Study Of Nivolumab/ Bevacizumab | Active, not recruiting | USA | 0 |
NCT02884648 | Phase II | Bevacizumab | Bevacizumab in Ovarian Cancer Patients With Disease at Second-look Surgery | Recruiting | USA | 0 |
NCT02900560 | Phase II | Azacitidine + Pembrolizumab | Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer | Terminated | USA | 0 |
NCT02901899 | Phase II | Guadecitabine + Pembrolizumab | Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Completed | USA | 0 |
NCT02915523 | Phase Ib/II | Avelumab Avelumab + Entinostat | Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer | Completed | USA | 0 |
NCT02922764 | Phase I | RGX-104 Ipilimumab + RGX-104 Nivolumab + RGX-104 Carboplatin + Pembrolizumab + Pemetrexed Disodium + RGX-104 | A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma | Active, not recruiting | USA | 0 |
NCT02923739 | Phase II | Bevacizumab + Emactuzumab + Paclitaxel Bevacizumab + Paclitaxel | Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer - REDIRECT | Terminated | USA | 0 |
NCT02943317 | Phase I | Defactinib Avelumab | Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer | Terminated | USA | 0 |
NCT02948101 | Phase II | Cyclophosphamide + PD 0360324 | Pre-Conditioning Effects of Anti-Macrophage Therapy Using PD 0360324 in Recurrent Platinum-Resistant Epithelial Ovarian Cancer | Withdrawn | USA | 0 |
NCT02948426 | Phase I | Interferon gamma + Peginterferon alfa-2b | Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer | Terminated | USA | 0 |
NCT02963831 | Phase Ib/II | Durvalumab + ONCOS-102 | A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies | Completed | USA | 0 |
NCT03018405 | Phase Ib/II | NKR-2 cells | A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) | Unknown status | USA | BEL | 0 |
NCT03038100 | Phase III | Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Paclitaxel | A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (IMagyn050) | Completed | USA | TUR | SWE | POL | NOR | ITA | ISR | GRC | FRA | FIN | ESP | DNK | DEU | CZE | BRA | BEL | AUT | AUS | 4 |
NCT03054909 | Phase I | Nogapendekin alfa inbakicept | QUILT-2.021: Phase I of IP Followed by SQ ALT-803 for Ovarian Cancer | Completed | USA | 0 |
NCT03078400 | Phase I | SPL-108 | Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer | Unknown status | USA | 0 |
NCT03079687 | Expanded access | Olaparib | Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | Approved for marketing | USA | 0 |
NCT03081702 | Phase Ib/II | Hydroxychloroquine + Itraconazole | A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer | Completed | CAN | 0 |
NCT03093155 | Phase II | Bevacizumab + Ixabepilone Ixabepilone | Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab | Completed | USA | 0 |
NCT03106987 | Phase III | Olaparib | A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer. (OReO) | Completed | POL | NOR | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CAN | BEL | 0 |
NCT03113487 | Phase II | MVAp53 + Pembrolizumab | P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Active, not recruiting | USA | 0 |
NCT03138408 | Phase I | SC-004 Budigalimab + SC-004 | SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers | Terminated | USA | 0 |
NCT03162562 | Phase I | Oregovomab + Poly ICLC | The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer | Terminated | USA | 0 |
NCT03206047 | Phase Ib/II | Atezolizumab + Guadecitabine Atezolizumab Atezolizumab + Guadecitabine + Rasdegafusp alfa | Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | USA | 0 |
NCT03206645 | Phase I | Carboplatin + Paclitaxel + Unesbulin | PTC-596 in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy | Completed | USA | 0 |
NCT03213964 | Phase I | Aldesleukin + FATE-NK100 | Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int | Completed | USA | 0 |
NCT03245892 | Phase I | Carboplatin + Nivolumab + Paclitaxel | A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab in Patients With Ovarian Cancer | Active, not recruiting | USA | 0 |
NCT03246074 | Phase I | Fostamatinib + Paclitaxel | Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer | Completed | USA | 0 |
NCT03287271 | Phase Ib/II | Defactinib | ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK | Recruiting | USA | 0 |
NCT03312114 | Phase II | Avelumab | Anti—PD-L1 and SAbR for Ovarian Cancer | Terminated | USA | 0 |
NCT03318900 | Phase I | Aldesleukin + Cyclophosphamide + Utomilumab | T Cell Immunotherapy for Advanced Ovarian Cancer | Completed | USA | 0 |
NCT03319628 | Phase I | XMT-1536 | First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b | Active, not recruiting | USA | 0 |
NCT03326193 | Phase II | Bevacizumab + Niraparib | Phase 2, A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy | Completed | USA | 0 |
NCT03394885 | Phase Ib/II | Atezolizumab + Carboplatin + Paclitaxel | Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer (AdORN) | Completed | USA | 0 |
NCT03398655 | Phase III | Paclitaxel Paclitaxel + VB-111 | A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL) (OVAL) | Completed | USA | POL | ISR | ESP | 1 |
NCT03410784 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab | Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer (MITO28MaNGOov4) | Recruiting | ITA | 0 |
NCT03430518 | Phase I | Durvalumab + Eribulin | Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer | Completed | USA | 0 |
NCT03462212 | Phase Ib/II | Bevacizumab + Carboplatin + Paclitaxel + Rucaparib Carboplatin + Paclitaxel + Rucaparib Bevacizumab + Carboplatin + Paclitaxel | Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination (MITO25) | Recruiting | ITA | 0 |
NCT03519178 | Phase II | PF-06873600 | A Study of PF-06873600 in People With Cancer | Active, not recruiting | USA | CAN | BGR | 3 |
NCT03522246 | Phase III | Rucaparib Nivolumab Nivolumab + Rucaparib | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) | Active, not recruiting | USA | TUR | SWE | ROU | POL | NZL | ITA | ISR | IRL | GRC | GBR | FIN | ESP | DNK | DEU | CZE | CAN | BEL | AUS | 5 |
NCT03558139 | Phase I | Avelumab + Hu5F9-G4 | A Trial of Hu5F9-G4 With Avelumab in Ovarian Cancer | Completed | USA | 0 |
NCT03564340 | Phase Ib/II | Cemiplimab + REGN4018 REGN4018 | Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Patients With Platinum-Resistant Ovarian Cancer | Recruiting | USA | NLD | ITA | ISR | GBR | FRA | ESP | BEL | AUS | 1 |
NCT03574779 | Phase II | Bevacizumab + Dostarlimab-gxly + Niraparib | Phase 2 Multicohort Study to Evaluate the Safety and Efficacy of Novel Treatment Combinations in Patients With Recurrent Ovarian Cancer (OPAL) | Active, not recruiting | USA | TUR | ESP | CAN | 0 |
NCT03579316 | Phase II | Olaparib Adavosertib + Olaparib | Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Active, not recruiting | USA | 0 |
NCT03596281 | Phase I | Pegylated liposomal doxorubicin + Pembrolizumab Bevacizumab + Pembrolizumab | Pembrolizumab in Combination With Bevacizumab and Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer (PEMBOV) | Completed | FRA | 0 |
NCT03607955 | Phase I | AVB-S6-500 + Carboplatin + Paclitaxel | Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy | Withdrawn | 0 | |
NCT03637764 | Phase Ib/II | Atezolizumab + Isatuximab Isatuximab | Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies | Terminated | USA | NLD | ITA | ESP | CZE | CAN | BEL | 1 |
NCT03642132 | Phase III | Bevacizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel + Talazoparib Avelumab + Carboplatin + Paclitaxel + Talazoparib | Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100) | Terminated | USA | ITA | IRL | BEL | AUS | 5 |
NCT03657043 | Phase II | Tisotumab vedotin-tftv | A Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen (innovaTV 208) | Completed | USA | ITA | IRL | ESP | DNK | BEL | 0 |
NCT03691376 | Phase I | Melphalan NY-ESO-1 TCR CD4- CD34+ HSC Aldesleukin Autologous NY-ESO-1-specific CD8-positive T cells | Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Terminated | USA | 0 |
NCT03704467 | Phase II | Bevacizumab + Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin Avelumab + Berzosertib + Carboplatin | Study of Avelumab + M6620 + Carboplatin in Poly (Adenosine Diphosphate Ribose [ADP]-Ribose) Polymerase Inhibitor (PARPi)-Resistant Recurrent Ovarian Cancer | Completed | USA | GBR | BEL | 0 |
NCT03732950 | Phase II | Pembrolizumab | Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer | Active, not recruiting | USA | 0 |
NCT03734692 | Phase Ib/II | Cisplatin + Pembrolizumab + Rintatolimod | Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer | Recruiting | USA | 0 |
NCT03735589 | Phase Ib/II | alphaDC1 + NK-like CTLs | Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Withdrawn | USA | 0 |
NCT03740165 | Phase III | Bevacizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Olaparib + Paclitaxel + Pembrolizumab Carboplatin + Olaparib + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab | Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) | Active, not recruiting | USA | TUR | POL | ITA | ISR | HUN | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | 8 |
NCT03748186 | Phase I | Luveltamab Tazevibulin | Study of STRO-002, an Anti-Folate Receptor Alpha (FolR?) Antibody Drug Conjugate in Ovarian & Endometrial Cancers | Completed | USA | ESP | 0 |
NCT03756818 | Phase I | Mivavotinib + Paclitaxel | TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03784677 | Phase I | SOR-C13 | SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors | Completed | USA | 0 |
NCT03824704 | Phase II | Nivolumab + Rucaparib | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | Terminated | USA | 0 |
NCT03836352 | Phase II | Maveropepimut-S + Pembrolizumab Cyclophosphamide + Maveropepimut-S + Pembrolizumab | Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | Active, not recruiting | USA | CAN | 0 |
NCT03861403 | Phase Ib/II | Avelumab + Cyclophosphamide + TRX518 | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors | Terminated | USA | 0 |
NCT03872206 | Phase Ib/II | HPN536 | Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression | Completed | USA | 0 |
NCT03934814 | Phase I | Lemzoparlimab Lemzoparlimab + Pembrolizumab Lemzoparlimab + Rituximab | Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma | Completed | USA | 1 |
NCT03943173 | Phase I | Olaparib | Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery | Active, not recruiting | USA | 0 |
NCT03959761 | Phase Ib/II | Nivolumab | Tolerance of Intraperitoneal (IP) Nivolumab After Extensive Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Ovarian Carcinoma (ICONIC) | Unknown status | FRA | 0 |
NCT04019288 | Phase Ib/II | AVB-S6-500 + Durvalumab | AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Completed | USA | 0 |
NCT04024878 | Phase I | NeoVax + Nivolumab | NeoVax With Nivolumab in Patients With Ovarian Cancer | Active, not recruiting | USA | 0 |
NCT04055649 | Phase II | ONC201 + Paclitaxel | ONC201 and Paclitaxel in Treating Patients With Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Recruiting | USA | 0 |
NCT04092270 | Phase I | Pegylated liposomal doxorubicin + Peposertib | A Study Combining the M3814 Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer Patients | Active, not recruiting | USA | 0 |
NCT04111978 | Phase III | Letrozole | MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) (MATAO) | Recruiting | DEU | CHE | AUT | 0 |
NCT04122625 | Phase Ib/II | Nivolumab + Xevinapant | Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 (SMARTPLUS-106) | Completed | USA | FRA | ESP | 0 |
NCT04152499 | Phase Ib/II | SKB264 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264) | Recruiting | USA | TUR | CAN | 2 |
NCT04182516 | Phase I | NMS-03305293 | Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors | Terminated | USA | ITA | GBR | BGR | 1 |
NCT04196257 | Phase I | BP1001-A BP1001-A + Paclitaxel | BP1001-A in Patients With Advanced or Recurrent Solid Tumors | Unknown status | USA | 0 |
NCT04239014 | Phase II | Olaparib Ceralasertib + Olaparib | A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment. (DUETTE) | Withdrawn | USA | ITA | ESP | CAN | 0 |
NCT04267939 | Phase I | Elimusertib + Niraparib | ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer | Terminated | USA | 0 |
NCT04274426 | Phase II | Carboplatin + Paclitaxel Carboplatin + Gemcitabine Carboplatin + Pegylated liposomal doxorubicin Carboplatin + Mirvetuximab Soravtansine | Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRalpha) High Recurrent Ovarian Cancer (MIROVA) | Active, not recruiting | DEU | 0 |
NCT04282044 | Phase I | CRX100 | Study of CRX100 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04300556 | Phase Ib/II | MORAb-202 | A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRa)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types | Recruiting | USA | GBR | FRA | ESP | 0 |
NCT04429542 | Phase I | BCA101 BCA101 + Pembrolizumab | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | Recruiting | USA | CAN | AUS | 0 |
NCT04469764 | Phase II | Abemaciclib + Anastrozole Abemaciclib + Letrozole Abemaciclib | Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer | Recruiting | USA | 0 |
NCT04482309 | Phase II | Trastuzumab deruxtecan | A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (DPT02) | Recruiting | USA | POL | NLD | ITA | GBR | ESP | CZE | CAN | BRA | BEL | AUS | 6 |
NCT04493619 | Phase Ib/II | Carboplatin + PLX2853 PLX2853 | PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer | Terminated | USA | CAN | 0 |
NCT04498520 | Phase I | Abexinostat + Fulvestrant + Palbociclib | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer | Withdrawn | 0 | |
NCT04516447 | Phase I | Pegylated liposomal doxorubicin + ZN-c3 Carboplatin + ZN-c3 | A Study of ZN-c3 in Patients With Platinum-Resistant Ovarian Cancer | Recruiting | USA | BGR | AUS | 4 |
NCT04519151 | Phase II | Lenvatinib + Pembrolizumab | Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer | Recruiting | ISR | 0 |
NCT04553133 | Phase II | PF-07104091 Letrozole + Palbociclib + PF-07104091 Palbociclib + PF-07104091 | PF-07104091 as a Single Agent and in Combination Therapy | Active, not recruiting | USA | BGR | ARG | 3 |
NCT04561817 | Phase II | Ipatasertib + Paclitaxel | To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer | Withdrawn | USA | 0 |
NCT04570839 | Phase Ib/II | BMS-986207 + COM701 + Nivolumab Nivolumab | COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. | Completed | USA | 0 |
NCT04590326 | Phase Ib/II | REGN4018 + REGN5668 Cemiplimab + REGN5668 | Study of REGN5668 Administered in Combination With Cemiplimab or REGN4018 in Adult Women With Recurrent Ovarian Cancer. | Recruiting | USA | FRA | ESP | BEL | 0 |
NCT04598321 | Phase I | Talazoparib | BrUOG 390: Neoadjuvant Treatment With Talazoparib | Terminated | USA | 0 |
NCT04630769 | Phase I | Aldesleukin + FT516 Aldesleukin + FT516 + MGA271 | FT516 and IL2 With Enoblituzumab for Ovarian Cancer | Completed | USA | 0 |
NCT04633239 | Phase I | Abemaciclib + Olaparib | Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer | Recruiting | USA | 0 |
NCT04670068 | Phase I | CAR.B7-H3T cells Cyclophosphamide + Fludarabine | Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian | Recruiting | USA | 0 |
NCT04676334 | Phase III | Rucaparib | CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib (CATCH-R) | Completed | POL | ITA | ISR | GBR | CAN | 1 |
NCT04706962 | Phase I | TH1902 | TH1902 in Patients With Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT04713514 | Phase II | OSE 2101 + Pembrolizumab OSE 2101 | OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC (TEDOVA) | Active, not recruiting | FRA | DEU | BEL | 0 |
NCT04726332 | Phase I | Abiraterone + Prednisone + XL102 Fulvestrant + XL102 XL102 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) | Terminated | USA | 0 |
NCT04742075 | Phase II | Olaparib Durvalumab + Olaparib Durvalumab + Olaparib + UV1 Telomerase peptide vaccine | Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer (DOVACC) | Recruiting | DNK | 0 |
NCT04753216 | Phase II | Bevacizumab + Liposomal irinotecan | Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Completed | USA | 0 |
NCT04781088 | Phase II | Lenvatinib + Paclitaxel + Pembrolizumab | Lenvatinib, Pembrolizumab, and Paclitaxel for the Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | USA | 0 |
NCT04787289 | Phase II | Bevacizumab | A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer | Recruiting | CAN | 0 |
NCT04809805 | Phase I | BAY2666605 | A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Parts of the Body and Other Types of Advanced Cancer | Terminated | USA | 0 |
NCT04840589 | Phase I | Ipilimumab + Nivolumab + ZEN-3694 Nivolumab + ZEN-3694 | Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors | Recruiting | USA | 0 |
NCT04887961 | Phase II | Pegylated liposomal doxorubicin + Trabectedin | Reprab Study: PLD + Trabectedin Rechallenge (MITO36) | Unknown status | ITA | 0 |
NCT04919629 | Phase II | Bevacizumab Bevacizumab + Pegcetacoplan + Pembrolizumab Pegcetacoplan + Pembrolizumab | APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion | Recruiting | USA | 0 |
NCT04931342 | Phase II | Cobimetinib Ado-trastuzumab emtansine Ipatasertib + Paclitaxel Atezolizumab + Bevacizumab | A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors | Active, not recruiting | USA | TUR | ITA | GBR | FRA | ESP | DEU | CZE | CHE | CAN | AUS | 2 |
NCT04991740 | Phase I | JNJ-78306358 | A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors | Completed | ISR | ESP | 0 |
NCT05001347 | Phase II | Uliledlimab | A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ) in Patients With Ovarian Cancer and Selected Solid Tumors | Completed | USA | 0 |
NCT05006794 | Phase I | GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies | Recruiting | USA | ISR | 0 |
NCT05009082 | Phase III | Carboplatin + Niraparib + Paclitaxel Bevacizumab + Niraparib Bevacizumab + Carboplatin + Paclitaxel | Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer | Recruiting | DEU | 0 |
NCT05041257 | Phase II | Mirvetuximab Soravtansine | Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO) | Active, not recruiting | USA | ITA | IRL | FRA | ESP | CAN | BEL | AUS | 0 |
NCT05086692 | Phase Ib/II | MDNA11 + Pembrolizumab | A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) | Recruiting | USA | CAN | AUS | 1 |
NCT05092360 | Phase III | Pembrolizumab ALKS 4230 Topotecan Paclitaxel Pegylated liposomal doxorubicin Gemcitabine ALKS 4230 + Pembrolizumab | Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab (ARTISTRY-7) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUT | AUS | 3 |
NCT05107674 | Phase I | NX-1607 | A Study of NX-1607 in Adults With Advanced Malignancies | Recruiting | USA | GBR | 0 |
NCT05116189 | Phase III | Bevacizumab + Docetaxel Bevacizumab + Paclitaxel + Pembrolizumab Bevacizumab + Docetaxel + Pembrolizumab Bevacizumab + Paclitaxel | Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65) | Active, not recruiting | USA | TUR | POL | NZL | NOR | NLD | ITA | ISR | IRL | GBR | FRA | FIN | DNK | DEU | CAN | BRA | BEL | AUS | 7 |
NCT05145569 | Phase I | Bintrafusp alfa + Carboplatin + Paclitaxel Carboplatin + Paclitaxel | Antitumor Activity of Neoadjuvant Chemotherapy With or Without BINTRAFUSP ALFA in Patients With Metastatic Advanced Stage Ovarian Cancer | Withdrawn | USA | 0 |
NCT05156892 | Phase I | Itraconazole + Tamoxifen | Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer (TICTOC) | Recruiting | AUS | 0 |
NCT05183984 | Phase II | Carboplatin + Niraparib + Paclitaxel Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Niraparib | Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer (NIRVANA-1) | Recruiting | ITA | FRA | ESP | 3 |
NCT05194072 | Phase I | SGN-B7H4V | A Study of SGN-B7H4V in Advanced Solid Tumors | Recruiting | USA | ITA | GBR | ESP | DEU | CAN | 0 |
NCT05198804 | Phase Ib/II | Niraparib + ZN-c3 | A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer | Active, not recruiting | USA | FRA | 0 |
NCT05199272 | Phase Ib/II | 23ME-00610 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | Active, not recruiting | USA | CAN | 0 |
NCT05231122 | Phase II | Bevacizumab + CDX-1140 + Pembrolizumab Bevacizumab + Pembrolizumab | Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer | Recruiting | USA | 0 |
NCT05233982 | Phase II | Olaparib | MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer (MITO 35a) | Recruiting | ITA | 0 |
NCT05257408 | Phase III | Nab-paclitaxel Nab-paclitaxel + Relacorilant | Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer | Active, not recruiting | USA | POL | ITA | ISR | HUN | GBR | FRA | ESP | CAN | BRA | BEL | AUS | ARG | 1 |
NCT05261490 | Phase Ib/II | Pegylated liposomal doxorubicin + TTI-622 | Study of TTI-622 in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer | Terminated | USA | 0 |
NCT05277051 | Phase I | GSK4381562 Dostarlimab-gxly + EOS-448 + GSK4381562 Dostarlimab-gxly + GSK4381562 | First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | FRA | ESP | CAN | AUS | 3 |
NCT05317078 | Phase I | AMG 794 | A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications | Terminated | USA | CHE | AUS | 0 |
NCT05325866 | Phase I | Bemarituzumab | A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301) | Recruiting | USA | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DNK | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 4 |
NCT05335993 | Phase II | Niraparib + Oregovomab | A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. | Active, not recruiting | USA | 0 |
NCT05403554 | Phase I | NI-1801 | A Study of NI-1801 in Patients With Mesothelin Expressing Solid Cancers | Recruiting | ITA | FRA | 0 |
NCT05445778 | Phase III | Bevacizumab + Mirvetuximab Soravtansine Bevacizumab | Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) | Recruiting | USA | TUR | SWE | POL | NOR | ITA | ISR | IRL | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BGR | BEL | AUS | ARG | 3 |
NCT05453825 | Phase II | Irinotecan + Navicixizumab Navicixizumab Navicixizumab + Paclitaxel | A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05456685 | Phase II | Carboplatin + Mirvetuximab Soravtansine | Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRalpha) Expressing, Platinum-sensitive Epithelial Ovarian Cancer | Active, not recruiting | USA | GBR | ESP | CAN | BEL | 1 |
NCT05467670 | Phase II | Doxorubicin + Evorpacept + Pembrolizumab | Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer | Recruiting | USA | 0 |
NCT05483933 | Phase I | Pegylated liposomal doxorubicin + SL-172154 Mirvetuximab Soravtansine + SL-172154 | Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers | Active, not recruiting | USA | GBR | ESP | CAN | 0 |
NCT05527184 | Phase I | IMGN151 | First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers | Recruiting | USA | 0 |
NCT05538091 | Phase II | Atezolizumab + Vismodegib | Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | Recruiting | USA | 0 |
NCT05579366 | Phase Ib/II | PRO1184 | PRO1184 for Advanced Solid Tumors (PRO1184-001) | Recruiting | USA | 1 |
NCT05585034 | Phase I | Pembrolizumab + XmAb808 | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb808 in Combination With Pembrolizumab in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05592626 | Phase Ib/II | STAR0602 | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors (START-001) | Recruiting | USA | FRA | ESP | CAN | 0 |
NCT05620134 | Phase Ib/II | JK08 | A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Active, not recruiting | ESP | BEL | 0 |
NCT05672095 | Phase Ib/II | Niraparib | Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer | Not yet recruiting | USA | 0 |
NCT05672459 | Phase Ib/II | IVS-3001 Cyclophosphamide + Fludarabine | A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors | Recruiting | USA | 0 |
NCT05691504 | Phase I | APG-1252 + Cobimetinib | Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers | Recruiting | USA | 0 |
NCT05708924 | Phase I | FT538 FT538 + MGA271 | MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | Suspended | USA | 0 |
NCT05735080 | Phase Ib/II | INX-315 | Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer (INX-315-01) | Recruiting | USA | AUS | 0 |
NCT05739981 | Phase II | Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + GEN-1 + Paclitaxel | A Phase II Study Evaluating the Effect of GEN-1 on SLL When Administered in Combination With Bevacizumab and NACT in Subjects Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer (MRD) | Recruiting | USA | 0 |
NCT05756907 | Phase Ib/II | Atezolizumab + SON-1010 SON-1010 | Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer | Recruiting | USA | AUS | 0 |
NCT05794659 | Phase II | Carboplatin + Paclitaxel + Sargramostim Carboplatin + Paclitaxel + pUMVC3-hIGFBP-2 vaccine + Sargramostim | Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer (Cornerstone4) | Not yet recruiting | USA | 0 |
NCT05836324 | Phase I | INCA33890 | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DNK | CHE | 1 |
NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advanced Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |
NCT05867251 | Phase Ib/II | ARTS-021 + Fulvestrant + Ribociclib ARTS-021 + Letrozole + Ribociclib ARTS-021 + Fulvestrant + Palbociclib ARTS-021 + Letrozole + Palbociclib ARTS-021 + Carboplatin Abemaciclib + ARTS-021 + Fulvestrant Abemaciclib + ARTS-021 + Letrozole ARTS-021 + Fulvestrant ARTS-021 | Study of AVZO-021 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05920798 | Phase Ib/II | FR alpha peptide vaccine + Pembrolizumab | A Study of FRaDCs for Ovarian Cancer | Recruiting | USA | 0 |
NCT05969041 | Phase I | MT-302 | Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors (MYE Symphony) | Recruiting | AUS | 0 |
NCT05983276 | Phase II | Carboplatin + Decitabine + Paclitaxel + Selinexor Carboplatin + Decitabine + Paclitaxel | Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer | Recruiting | USA | 0 |
NCT05985655 | Phase Ib/II | GTAEXS617 | Study to Assess GTAEXS617 in Patients With Advanced Solid Tumors (ELUCIDATE) | Recruiting | GBR | BEL | 0 |
NCT05990192 | Phase II | Niraparib | SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy (SOPRANO) | Recruiting | GBR | 0 |
NCT06028932 | Phase II | Sacituzumab govitecan-hziy | A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients | Recruiting | USA | 0 |
NCT06040970 | Phase Ib/II | Cisplatin + Sacituzumab govitecan-hziy | Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer | Recruiting | USA | 0 |
NCT06056323 | Phase Ib/II | HB0045 | A Study of HB0045 Injection in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06083844 | Phase II | Bevacizumab + Cyclophosphamide + Pembrolizumab | Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy | Recruiting | USA | 0 |
NCT06087289 | Phase Ib/II | Carboplatin + KAND567 | A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (KANDOVA) | Recruiting | SWE | NOR | DNK | 0 |
NCT06121401 | FDA approved | Bevacizumab + Olaparib | First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients (IOLANTHE) | Recruiting | ITA | 0 |
NCT06130254 | Phase I | Adagrasib + Olaparib | Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers | Recruiting | USA | 0 |
NCT06171789 | Phase Ib/II | PRO1107 | PRO1107 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06172478 | Phase II | Patritumab deruxtecan | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 2 |
NCT06305299 | Phase I | Cyclophosphamide + Fludarabine iC9-CAR.B7-H3 T-cells | Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells | Recruiting | USA | 0 |
NCT06321484 | Phase I | CIML-NK cells + Nogapendekin alfa inbakicept | Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer | Recruiting | USA | 0 |
NCT06365853 | Phase II | Mirvetuximab Soravtansine | A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression | Recruiting | USA | ITA | IRL | FRA | ESP | CAN | BEL | AUS | 0 |
NCT06400472 | Phase I | LY4170156 | A Study of LY4170156 in Participants With Selected Advanced Solid Tumors | Recruiting | USA | FRA | ESP | AUS | 2 |
NCT06433219 | Phase II | M1774 + Niraparib M1774 + M4076 | Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) | Recruiting | USA | POL | ITA | GBR | FRA | ESP | DNK | CHE | BEL | 0 |
NCT06466187 | Phase I | SGN-MesoC2 | A Study of SGN-MesoC2 in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06469281 | Phase I | 27T51 27T51 + Bevacizumab + Cemiplimab 27T51 + Cemiplimab | A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers | Recruiting | USA | 0 |
NCT06547840 | Phase I | MOv18IgE | A Study of MOv18 IgE in Folate Receptor Alpha-expressing Platinum Resistant Ovarian Cancer | Recruiting | GBR | 0 |
NCT06560632 | Phase I | Olaparib + RP-3467 RP-3467 | Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors (POLAR) | Recruiting | USA | 0 |
NCT06594679 | Phase Ib/II | Abemaciclib + Niraparib | A Study of Niraparib in Combination with Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL) (NICHOL) | Not yet recruiting | ITA | 0 |
NCT06638931 | Phase II | Nivolumab | Agnostic Therapy in Rare Solid Tumors (ANTARES) | Recruiting | BRA | 0 |
NCT06710288 | Phase II | Gemcitabine + m-ceNK cells + Nogapendekin alfa inbakicept | A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer | Recruiting | USA | 0 |